Corrigendum to "Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms" [Vaccine 68 (2025) 127942].
- DOI
- 10.1016/j.vaccine.2026.128267
- Published
- 2026 Mar 7
- Container
- Vaccine
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.vaccine.2026.128267,
title = {Corrigendum to "Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms" [Vaccine 68 (2025) 127942].},
author = {Saito T and Couzinet A and Suzuki T and Shimomura M and Ryo A and Miyakawa K and Katayama Y and Nakatsura T},
year = {2026},
journal = {Vaccine},
doi = {10.1016/j.vaccine.2026.128267},
url = {https://doi.org/10.1016/j.vaccine.2026.128267}
}RIS
TY - JOUR TI - Corrigendum to "Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms" [Vaccine 68 (2025) 127942]. AU - Saito T AU - Couzinet A AU - Suzuki T AU - Shimomura M AU - Ryo A AU - Miyakawa K AU - Katayama Y AU - Nakatsura T PY - 2026 JO - Vaccine DO - 10.1016/j.vaccine.2026.128267 UR - https://doi.org/10.1016/j.vaccine.2026.128267 ER -
APA
T, S., A, C., T, S., M, S., A, R., K, M., Y, K., & T, N. (2026). Corrigendum to "Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms" [Vaccine 68 (2025) 127942].. Vaccine. https://doi.org/10.1016/j.vaccine.2026.128267
Source records
- pubmed · retrieved 2026-09-26T21:04:05.493Z
- europe-pmc · retrieved 2026-09-26T21:04:05.507Z